VIDEO: TNF inhibitors safe for RA-ILD, but ‘unlikely they have much efficacy’
Click Here to Manage Email Alerts
SAN DIEGO — In this video, Jeffrey A. Sparks, MD, MMSc, spoke with Healio about the safety of TNF inhibitors compared with alternative targeted therapies for patients with rheumatoid arthritis-associated interstitial lung disease.
The findings were presented at ACR Convergence 2023.
“This kind of affirms that maybe it is safe to use TNF inhibitors in [rheumatoid arthritis-associated interstitial lung disease] RA-ILD patients which I think is a bit practice-changing [because] it is something that is typically avoided in RA-ILD patients,” said Sparks, an associate professor of medicine at Harvard Medical School and an associate program director of the Rheumatology Fellowship, director of Immuno-Oncology and Autoimmunity and director of the Joint Biology Consortium Human Biosamples Core at Brigham and Women’s Hospital. “However, I would say that TNF inhibitors, while they might be safe from a respiratory perspective, it’s probably unlikely they have much efficacy. So, I think the jury’s still out as far as what is the best medication to use when someone has active RA and active lung disease.”
Collapse
England B, et al. Abstract 1582. Presented at: ACR Convergence 2023; Nov. 10-15, 2023; San Diego.
Click Here to Manage Email Alerts